Literature DB >> 15185718

HCV and HIV: a tale of two viruses.

Kenneth E Sherman1.   

Abstract

Liver disease has emerged as a major cause of morbidity and mortality in patients infected with the human immunodeficiency virus. Hepatic injury is highly associated with hepatitis C virus (HCV) infection, though hepatitis B virus and drug-induced hepatotoxicity are also important cofactors. HCV coinfection is linked to increased hepatic fibrosis progression, leading to development of cirrhosis and liver failure earlier than in HCV monoinfected patients. Initiation of highly active antiretroviral treatment regimens may paradoxically increase HCV loads. Some data suggest that HCV coinfection may hasten progression of AIDS, but this remains controversial. Three major randomized clinical trials demonstrate improved efficacy of peginterferon with ribavirin for treatment of HCV in coinfected subjects compared to those with HCV alone. However, response rates are lower than those observed in patients with HCV monoinfection. Sustained virologic response rates of 27% to 40% are reported.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15185718

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  5 in total

1.  Optimizing treatment for African Americans and Latinos with HIV/AIDS.

Authors:  Richard O Butcher; Rodney G Hood; Wilbert C Jordan
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

2.  Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?

Authors:  Joseph M Mrus; Kenneth E Sherman; Anthony C Leonard; Susan N Sherman; Karen L Mandell; Joel Tsevat
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

Review 3.  Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline.

Authors:  Carrie L Jennings; Kenneth E Sherman
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

4.  Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Authors:  Xiaozhen Zhang; Astrid C Frank; Christine M Gille; Marybeth Daucher; Juraj Kabat; Steven Becker; Richard A Lempicki; Karoll J Cortez; Michael A Polis; G Mani Subramanian; Shyam Kottilil
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

5.  The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Authors:  Philippe A Gallay; Michael D Bobardt; Udayan Chatterji; Daniel J Trepanier; Daren Ure; Cosme Ordonez; Robert Foster
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.